NovaBay Pharmaceuticals, Inc. Logo

NovaBay Pharmaceuticals, Inc.

Develops and commercializes eyecare, skincare, and wound care products.

NBY | US

Overview

Corporate Details

ISIN(s):
US66987P2011
LEI:
Country:
United States of America
Address:
2000 POWELL STREET, SUITE 1150, 94608 EMERYVILLE

Description

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes scientifically-created and clinically-proven products for the eyecare, skincare, and wound care markets. The company's core technology is a proprietary, stable formulation of hypochlorous acid. Its leading product is Avenova®, an antimicrobial lid and lash solution available over-the-counter for eye hygiene. In the wound care sector, NovaBay manufactures and sells products under the NeutroPhase® and PhaseOne® brands, which utilize its hypochlorous acid technology to aid in cleansing and debridement. The company focuses on providing accessible, problem-solving solutions for improved well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NovaBay Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NovaBay Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NovaBay Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELADON PHARMACEUTICALS PLC Logo
Researches, cultivates, and manufactures cannabinoid-based medicines for chronic pain.
United Kingdom
CEL
Celemics, Inc. Logo
Develops NGS target enrichment solutions for research and clinical applications.
South Korea
331920
Develops radiopharmaceuticals and radioligand therapies for oncology.
South Korea
308430
CELL BIOTECH CO ., LTD Logo
Develops and manufactures probiotic solutions using patented dual-coating technology.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based immunotherapies for severe inflammatory and allergic diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.
United States of America
CLRB
Cellectis Logo
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
France
ALCLS
Cellid Co., Ltd. Logo
Develops immunotherapeutic vaccines for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Researches and develops health foods, derma-cosmetics, and OTC pharmaceuticals.
South Korea
471820
CellSeed Inc. Logo
Develops and commercializes cell sheet engineering for regenerative medicine.
Japan
7776

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.